• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一项关于日本疫苗短缺期间 17D-204 黄热病疫苗安全性的全国前瞻性队列研究。

A nationwide prospective cohort study on safety of the 17D-204 yellow fever vaccine during a vaccine shortage in Japan.

机构信息

Disease Control and Prevention Center, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan.

Division of Quarantine and Sanitation, Chubu Airport Quarantine Office, Nagoya Quarantine Station, Nagoya 479-0881, Japan.

出版信息

J Travel Med. 2023 Apr 5;30(2). doi: 10.1093/jtm/taac070.

DOI:10.1093/jtm/taac070
PMID:35640301
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10075058/
Abstract

In response to the vaccine shortage of yellow fever vaccine (YF-VAX) due to manufacturing delays, the unapproved 17D-204 YF-VAX was used as an investigator-initiated clinical trial in Japan. The vaccine was administered to 11 279 participants in 19 YF vaccination centres in Japan, and few serious adverse events were observed.

摘要

由于黄热病疫苗（YF-VAX）的生产延迟，导致疫苗短缺，日本因此开展了一项研究者发起的临床试验，使用了未经批准的 17D-204 YF-VAX。该疫苗在日本的 19 个 YF 疫苗接种中心对 11279 名参与者进行了接种，观察到的严重不良事件很少。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/907a/10075058/89f428f883ca/taac070f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/907a/10075058/89f428f883ca/taac070f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/907a/10075058/89f428f883ca/taac070f1.jpg

相似文献

1
A nationwide prospective cohort study on safety of the 17D-204 yellow fever vaccine during a vaccine shortage in Japan.一项关于日本疫苗短缺期间 17D-204 黄热病疫苗安全性的全国前瞻性队列研究。
J Travel Med. 2023 Apr 5;30(2). doi: 10.1093/jtm/taac070.
2
Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children: implications for the Brazilian National Immunization Program.17DD和世界卫生组织17D-213/77黄热病疫苗在儿童中的免疫原性和反应原性的随机、双盲、多中心研究：对巴西国家免疫规划的影响
Vaccine. 2007 Apr 20;25(16):3118-23. doi: 10.1016/j.vaccine.2007.01.053. Epub 2007 Jan 22.
3
Yellow fever vaccine safety: a reality or a myth?黄热病疫苗的安全性：是事实还是虚构？
Vaccine. 2002 Nov 1;20(31-32):3627-8. doi: 10.1016/s0264-410x(02)00409-7.
4
Immune activation alters cellular and humoral responses to yellow fever 17D vaccine.免疫激活会改变对黄热病17D疫苗的细胞和体液反应。
J Clin Invest. 2014 Jul;124(7):3147-58. doi: 10.1172/JCI75429. Epub 2014 Jun 9.
5
Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in mice.质粒DNA在体外启动黄热病疫苗的复制，并在小鼠体内引发病毒特异性免疫反应。
Virology. 2014 Nov;468-470:28-35. doi: 10.1016/j.virol.2014.07.050. Epub 2014 Aug 16.
6
Clinical evidence for the immunogenicity and immune persistence of vaccination with yellow fever virus strain 17D in Chinese peacekeepers deployed to Africa.中国维和人员接种黄热病毒 17D 株疫苗的免疫原性和免疫持久性的临床证据。
Antiviral Res. 2019 Feb;162:1-4. doi: 10.1016/j.antiviral.2018.12.001. Epub 2018 Dec 6.
7
A Chimeric Japanese Encephalitis Vaccine Protects against Lethal Yellow Fever Virus Infection without Inducing Neutralizing Antibodies.一种嵌合日本脑炎疫苗可预防致死性黄热病病毒感染而不诱导中和抗体。
mBio. 2020 Apr 7;11(2):e02494-19. doi: 10.1128/mBio.02494-19.
8
Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?黄热病疫苗——它是如何起作用的，以及为什么会发生罕见的严重不良事件？
Curr Opin Immunol. 2009 Jun;21(3):308-13. doi: 10.1016/j.coi.2009.05.018. Epub 2009 Jun 10.
9
Attenuation of Live-Attenuated Yellow Fever 17D Vaccine Virus Is Localized to a High-Fidelity Replication Complex.活减毒黄热病 17D 疫苗病毒的衰减定位于高保真复制复合物。
mBio. 2019 Oct 22;10(5):e02294-19. doi: 10.1128/mBio.02294-19.
10
Is a dose of 17D vaccine in the current context of Yellow Fever enough?在当前黄热病的背景下，一剂17D疫苗是否足够？
Braz J Microbiol. 2018 Jul-Sep;49(3):683-684. doi: 10.1016/j.bjm.2018.02.003. Epub 2018 Mar 13.

引用本文的文献

1
Safety and Efficacy of Vaccination During Lactation: A Comprehensive Review of Vaccines for Maternal and Infant Health Utilizing a Large Language Model Citation Screening System.哺乳期接种疫苗的安全性和有效性：利用大语言模型引文筛选系统对母婴健康疫苗的全面综述
Vaccines (Basel). 2025 Mar 25;13(4):350. doi: 10.3390/vaccines13040350.
2
Yellow Jack: a modern threat to Asia-Pacific countries?黄热病：对亚太国家的现代威胁？
Npj Viruses. 2025 Apr 24;3(1):34. doi: 10.1038/s44298-024-00079-5.
3
Enhanced safety surveillance of STAMARIL® yellow fever vaccine provided under the expanded access investigational new drug program in the USA.

本文引用的文献

1
Clinical trial with unlicensed yellow fever vaccine in Japan.在日本使用未经许可的黄热病疫苗进行的临床试验。
J Travel Med. 2019 Sep 2;26(6). doi: 10.1093/jtm/tay151.
2
Fractional dosing of yellow fever vaccine during shortages: perspective from Canada.黄热病疫苗短缺期间的分次给药：来自加拿大的观点
J Travel Med. 2018 Jan 1;25(1). doi: 10.1093/jtm/tay098.
3
Update: Temporary Total Depletion of U.S. Licensed Yellow Fever Vaccine for Civilian Travelers Addressed by Investigational New Drug Use of Imported Stamaril Vaccine.最新消息：通过进口Stamaril疫苗的新药研究性使用解决美国民用旅行者许可黄热病疫苗暂时全面短缺问题。
美国扩大准入研究新药方案下使用的 STAMARIL®黄热病疫苗的强化安全性监测。
J Travel Med. 2023 Nov 18;30(7). doi: 10.1093/jtm/taad037.
MMWR Morb Mortal Wkly Rep. 2017 Jul 28;66(29):780. doi: 10.15585/mmwr.mm6629a4.
4
Overview of FDA's Expanded Access Program for Investigational Drugs.美国食品药品监督管理局（FDA）研究性药物扩大使用项目概述。
Ther Innov Regul Sci. 2017 Mar 1;51(2):177-179. doi: 10.1177/2168479017694850.
5
Addressing a Yellow Fever Vaccine Shortage - United States, 2016-2017.应对黄热病疫苗短缺问题——美国，2016 - 2017年
MMWR Morb Mortal Wkly Rep. 2017 May 5;66(17):457-459. doi: 10.15585/mmwr.mm6617e2.
6
Comparative study of adverse events after yellow fever vaccination between elderly and non-elderly travellers: questionnaire survey in Japan over a 1-year period.老年与非老年旅行者黄热病疫苗接种后不良事件的比较研究：日本为期1年的问卷调查
J Travel Med. 2016 Mar 28;23(3). doi: 10.1093/jtm/taw012. Print 2016 Mar.
7
Active assessment of adverse events following yellow fever vaccination of persons aged 60 years and more.对 60 岁及以上人群接种黄热病疫苗后的不良事件进行主动评估。
Hum Vaccin Immunother. 2013 Feb;9(2):277-82. doi: 10.4161/hv.22714. Epub 2013 Jan 4.
8
Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial.两种黄热病17D疫苗（ARILVAX和YF-VAX）在一项III期多中心双盲临床试验中的安全性和免疫原性比较
Am J Trop Med Hyg. 2002 May;66(5):533-41. doi: 10.4269/ajtmh.2002.66.533.